Analyzing gut bacteria in pancreatic diseases
Microbial Diversity of Pancreatic Diseases
This study looks at the gut bacteria in people with pancreatic cancer, other pancreatic diseases, and healthy individuals to see how they differ and if they can help us understand these conditions better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 330 (estimated) |
| Ages | 3 Years to 85 Years |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT03809247 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the digestive flora structure in patients with pancreatic cancer compared to those with other pancreatic diseases and healthy individuals. Participants will provide samples such as stool, blood, and digestive secretions, with additional tissue samples collected from those undergoing surgery. The goal is to identify differences in microbial communities among these groups and to uncover potential biomarkers and pathogenic mechanisms related to pancreatic diseases.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 3 to 85 years with confirmed pancreatic cancer or other pancreatic diseases who are eligible for surgery or ERCP.
Not a fit: Patients with serious cardiovascular disease, active infections, or a history of other cancers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the identification of new biomarkers for early detection and treatment of pancreatic diseases.
How similar studies have performed: While studies on microbial diversity in relation to various diseases exist, this specific approach focusing on pancreatic diseases is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 3 years old, ≤ 85 years old; * After MDT discussion, routine surgery or ERCP can be performed, and the postoperative pathology is clear as pancreatic cancer and other pancreatic diseases; * There is no serious damage to heart, liver and kidney function; Exclusion Criteria: * Women who are breast-feeding during pregnancy and after pregnancy; * Patients with evidence of sensory or motor neuropathy; * Those who have a clear cardiovascular disease, severe associated disease or active infection, including known HIV infection; * Those who have a history of other cancers; * Those who are allergic to drugs or their excipients
Where this trial is running
Shanghai, Shanghai
- Ruijin Hospital — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Wei WANG, Dr. — Ruijin Hospital
- Study coordinator: Wei WANG, Dr.
- Email: wangwei_0306@163.com
- Phone: +86-13761648121
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.